AmBase Shares Outstanding 2010-2024 | ABCP
AmBase shares outstanding from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
AmBase Annual Shares Outstanding (Millions of Shares) |
2024 |
74 |
2023 |
41 |
2022 |
41 |
2021 |
41 |
2020 |
41 |
2019 |
41 |
2018 |
41 |
2017 |
41 |
2016 |
41 |
2015 |
41 |
2014 |
41 |
2013 |
42 |
2012 |
43 |
2011 |
43 |
2010 |
43 |
2009 |
43 |
AmBase Quarterly Shares Outstanding (Millions of Shares) |
2024-12-31 |
74 |
2024-09-30 |
85 |
2024-06-30 |
85 |
2024-03-31 |
41 |
2023-12-31 |
41 |
2023-09-30 |
41 |
2023-06-30 |
41 |
2023-03-31 |
41 |
2022-12-31 |
41 |
2022-09-30 |
41 |
2022-06-30 |
41 |
2022-03-31 |
41 |
2021-12-31 |
41 |
2021-09-30 |
41 |
2021-06-30 |
41 |
2021-03-31 |
41 |
2020-12-31 |
41 |
2020-09-30 |
41 |
2020-06-30 |
41 |
2020-03-31 |
41 |
2019-12-31 |
41 |
2019-09-30 |
41 |
2019-06-30 |
41 |
2019-03-31 |
41 |
2018-12-31 |
41 |
2018-09-30 |
41 |
2018-06-30 |
41 |
2018-03-31 |
41 |
2017-12-31 |
41 |
2017-09-30 |
41 |
2017-06-30 |
41 |
2017-03-31 |
41 |
2016-12-31 |
41 |
2016-09-30 |
41 |
2016-06-30 |
41 |
2016-03-31 |
41 |
2015-12-31 |
41 |
2015-09-30 |
41 |
2015-06-30 |
41 |
2015-03-31 |
41 |
2014-12-31 |
41 |
2014-09-30 |
41 |
2014-06-30 |
41 |
2014-03-31 |
41 |
2013-12-31 |
42 |
2013-09-30 |
42 |
2013-06-30 |
43 |
2013-03-31 |
43 |
2012-12-31 |
43 |
2012-09-30 |
43 |
2012-06-30 |
43 |
2012-03-31 |
43 |
2011-12-31 |
43 |
2011-09-30 |
43 |
2011-06-30 |
43 |
2011-03-31 |
43 |
2010-12-31 |
43 |
2010-09-30 |
43 |
2010-06-30 |
43 |
2010-03-31 |
43 |
2009-12-31 |
43 |
2009-09-30 |
43 |
2009-06-30 |
43 |
2009-03-31 |
43 |
Sector |
Industry |
Market Cap |
Revenue |
Finance |
FIN-INVEST MGMT |
$0.026B |
$0.000B |
AmBase Corporation acts as investment banker/financial advisor toSDG, Inc. and all of its subsidiaries and affiliates. SDG, Inc. is a development stage company that specializes in reating new technology-specific companies that are dedicated to the clinical and commercial development of proprietary, targeted liposomal delivery systems for pharmaceutical therapies and consumer product ingredients.
|